Enolen Implant Cuts Localized Prostate Tumor Volume by 84% in Early Study

Enolen is an investigational anti‑androgen implant designed to deliver enzalutamide directly inside the prostate, aiming to shrink localized prostate tumors while minimizing systemic exposure to the drug. In data from a National Cancer Institute–led phase‑1 study, the device produced an 84% reduction in measurable tumor volume on MRI over roughly five weeks in men scheduled for radical prostatectomy.

The trial enrolled patients with low‑ to intermediate‑risk, localized prostate adenocarcinoma who were already planning to have their prostate removed. Before surgery, each participant underwent multiparametric prostate MRI, followed by implantation of up to 16 Enolen devices into the prostate. The implants are designed as sustained‑release reservoirs that continuously release enzalutamide, a potent anti‑androgen already approved systemically for advanced prostate cancer, directly into the prostate tissue.

In the reported cohort, MRI‑based tumor‑volume measurements in 18 evaluable patients showed a mean 84% decrease in tumor size between baseline and the pre‑surgical scan, with the surgical procedure occurring about 6–12 weeks after implantation. Analyses also detected high concentrations of enzalutamide within the prostate while systemic drug levels remained low, consistent with localized delivery. No delays to surgery were attributed to the implants, and adverse‑event profiles were generally limited to procedure‑related events similar to those seen with prostate biopsy rather than typical systemic hormonal‑therapy toxicities.

Systemic markers such as testosterone and PSA were also monitored, and the preliminary signals suggested substantial local activity without dramatic changes in circulating hormones (i.e., no sexual dysfunction attributable to testosterone suppression) or typical systemic side effects. The phase‑1 program is being expanded to additional cohorts to explore different numbers of implants, timing of surgery, and longer‑term hormone and quality‑of‑life endpoints.

Clinically, Enolen represents an attempt to shift how androgen‑directed therapy is used in early‑stage prostate cancer, by confining drug exposure to the prostate rather than bathing the whole body in anti‑androgens. If later-phase testing confirms the safety and tumor‑reduction signals seen so far, this approach could become a neoadjuvant focal strategy for men with localized disease, potentially shrinking tumors before surgery and reducing the risk of positive margins while avoiding many of the long‑term consequences of systemic hormone deprivation.

Source.